These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1423 related articles for article (PubMed ID: 33958745)

  • 1. Identification and characterization of a monoclonal antibody blocking the SARS-CoV-2 spike protein-ACE2 interaction.
    Yuan M; Wan Y; Liu C; Li Y; Liu Z; Lin C; Chen J
    Cell Mol Immunol; 2021 Jun; 18(6):1562-1564. PubMed ID: 33958745
    [No Abstract]   [Full Text] [Related]  

  • 2. Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern.
    Deshpande A; Harris BD; Martinez-Sobrido L; Kobie JJ; Walter MR
    Front Immunol; 2021; 12():691715. PubMed ID: 34149735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bifunctional molecules targeting SARS-CoV-2 spike and the polymeric Ig receptor display neutralization activity and mucosal enrichment.
    White I; Tamot N; Doddareddy R; Ho J; Jiao Q; Harvilla PB; Yang TY; Geist B; Borrok MJ; Truppo MD; Ganesan R; Chowdhury P; Zwolak A
    MAbs; 2021; 13(1):1987180. PubMed ID: 34693867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FN3-based monobodies selective for the receptor binding domain of the SARS-CoV-2 spike protein.
    Miller CJ; McGinnis JE; Martinez MJ; Wang G; Zhou J; Simmons E; Amet T; Abdeen SJ; Van Huysse JW; Bowsher RR; Kay BK
    N Biotechnol; 2021 May; 62():79-85. PubMed ID: 33556628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein.
    Johnson MC; Lyddon TD; Suarez R; Salcedo B; LePique M; Graham M; Ricana C; Robinson C; Ritter DG
    J Virol; 2020 Oct; 94(21):. PubMed ID: 32788194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human neutralizing antibodies elicited by SARS-CoV-2 infection.
    Ju B; Zhang Q; Ge J; Wang R; Sun J; Ge X; Yu J; Shan S; Zhou B; Song S; Tang X; Yu J; Lan J; Yuan J; Wang H; Zhao J; Zhang S; Wang Y; Shi X; Liu L; Zhao J; Wang X; Zhang Z; Zhang L
    Nature; 2020 Aug; 584(7819):115-119. PubMed ID: 32454513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The ACE2-binding Interface of SARS-CoV-2 Spike Inherently Deflects Immune Recognition.
    Hattori T; Koide A; Noval MG; Panchenko T; Romero LA; Teng KW; Tada T; Landau NR; Stapleford KA; Koide S
    J Mol Biol; 2021 Feb; 433(3):166748. PubMed ID: 33310017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid response flow cytometric assay for the detection of antibody responses to SARS-CoV-2.
    Lapuente D; Maier C; Irrgang P; Hübner J; Peter AS; Hoffmann M; Ensser A; Ziegler K; Winkler TH; Birkholz T; Kremer AE; Steininger P; Korn K; Neipel F; Überla K; Tenbusch M
    Eur J Clin Microbiol Infect Dis; 2021 Apr; 40(4):751-759. PubMed ID: 33078221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation.
    Hurlburt NK; Seydoux E; Wan YH; Edara VV; Stuart AB; Feng J; Suthar MS; McGuire AT; Stamatatos L; Pancera M
    Nat Commun; 2020 Oct; 11(1):5413. PubMed ID: 33110068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A single dose of self-transcribing and replicating RNA-based SARS-CoV-2 vaccine produces protective adaptive immunity in mice.
    de Alwis R; Gan ES; Chen S; Leong YS; Tan HC; Zhang SL; Yau C; Low JGH; Kalimuddin S; Matsuda D; Allen EC; Hartman P; Park KJ; Alayyoubi M; Bhaskaran H; Dukanovic A; Bao Y; Clemente B; Vega J; Roberts S; Gonzalez JA; Sablad M; Yelin R; Taylor W; Tachikawa K; Parker S; Karmali P; Davis J; Sullivan BM; Sullivan SM; Hughes SG; Chivukula P; Ooi EE
    Mol Ther; 2021 Jun; 29(6):1970-1983. PubMed ID: 33823303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Avian antibodies (IgY) targeting spike glycoprotein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) inhibit receptor binding and viral replication.
    Artman C; Brumfield KD; Khanna S; Goepp J
    PLoS One; 2021; 16(5):e0252399. PubMed ID: 34048457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation.
    Seydoux E; Homad LJ; MacCamy AJ; Parks KR; Hurlburt NK; Jennewein MF; Akins NR; Stuart AB; Wan YH; Feng J; Whaley RE; Singh S; Boeckh M; Cohen KW; McElrath MJ; Englund JA; Chu HY; Pancera M; McGuire AT; Stamatatos L
    Immunity; 2020 Jul; 53(1):98-105.e5. PubMed ID: 32561270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Collection of Monoclonal Antibodies Targeting SARS-CoV-2 Proteins.
    Pribanić Matešić M; Kučan Brlić P; Lenac Roviš T; Mačak Šafranko Ž; Chaouat AE; Miklić K; Malić S; Ivanković N; Schubert M; Bertoglio F; Markotić A; Mandelboim O; Jonjić S; Brizić I
    Viruses; 2022 Feb; 14(2):. PubMed ID: 35216036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Computational design and modeling of nanobodies toward SARS-CoV-2 receptor binding domain.
    Yang J; Zhang Z; Yang F; Zhang H; Wu H; Zhu F; Xue W
    Chem Biol Drug Des; 2021 Jul; 98(1):1-18. PubMed ID: 33894099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor.
    Chen X; Li R; Pan Z; Qian C; Yang Y; You R; Zhao J; Liu P; Gao L; Li Z; Huang Q; Xu L; Tang J; Tian Q; Yao W; Hu L; Yan X; Zhou X; Wu Y; Deng K; Zhang Z; Qian Z; Chen Y; Ye L
    Cell Mol Immunol; 2020 Jun; 17(6):647-649. PubMed ID: 32313207
    [No Abstract]   [Full Text] [Related]  

  • 16. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2.
    Chi X; Yan R; Zhang J; Zhang G; Zhang Y; Hao M; Zhang Z; Fan P; Dong Y; Yang Y; Chen Z; Guo Y; Zhang J; Li Y; Song X; Chen Y; Xia L; Fu L; Hou L; Xu J; Yu C; Li J; Zhou Q; Chen W
    Science; 2020 Aug; 369(6504):650-655. PubMed ID: 32571838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutations derived from horseshoe bat ACE2 orthologs enhance ACE2-Fc neutralization of SARS-CoV-2.
    Mou H; Quinlan BD; Peng H; Liu G; Guo Y; Peng S; Zhang L; Davis-Gardner ME; Gardner MR; Crynen G; DeVaux LB; Voo ZX; Bailey CC; Alpert MD; Rader C; Gack MU; Choe H; Farzan M
    PLoS Pathog; 2021 Apr; 17(4):e1009501. PubMed ID: 33836016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of multivalent nanobodies blocking SARS-CoV-2 infection by targeting RBD of spike protein.
    Lu Q; Zhang Z; Li H; Zhong K; Zhao Q; Wang Z; Wu Z; Yang D; Sun S; Yang N; Zheng M; Chen Q; Long C; Guo W; Yang H; Nie C; Tong A
    J Nanobiotechnology; 2021 Jan; 19(1):33. PubMed ID: 33514385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microfluidic characterisation reveals broad range of SARS-CoV-2 antibody affinity in human plasma.
    Schneider MM; Emmenegger M; Xu CK; Condado Morales I; Meisl G; Turelli P; Zografou C; Zimmermann MR; Frey BM; Fiedler S; Denninger V; Jacquat RP; Madrigal L; Ilsley A; Kosmoliaptsis V; Fiegler H; Trono D; Knowles TP; Aguzzi A
    Life Sci Alliance; 2022 Feb; 5(2):. PubMed ID: 34848436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. COVID-19-A Theory of Autoimmunity Against ACE-2 Explained.
    McMillan P; Dexhiemer T; Neubig RR; Uhal BD
    Front Immunol; 2021; 12():582166. PubMed ID: 33833750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 72.